VANDA PHARMS INC
SpecialtyVANDA PHARMS INC is a specialty pharmaceutical company focused on Neurology. Key products include PONVORY.
FDA Novel Drug Designations
(2021-2025)VANDA PHARMS INC at a Glance
- Fast trial execution (13 months median completion)
Upcoming FDA Decisions
Full Calendar →VANDA PHARMS INC's Key Drugs
VANDA PHARMS INC's core commercial portfolio centers on PONVORY, HETLIOZ, HETLIOZ LQ, spanning Neurology — its most strategically important drugs approved in the last 15 years.
VANDA PHARMS INC's Recent FDA Approvals
VANDA PHARMS INC secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
VANDA PHARMS INC's Therapeutic Areas
VANDA PHARMS INC's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
VANDA PHARMS INC's Top Competitors
VANDA PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
VANDA PHARMS INC Pipeline Snapshot
Active clinical trials for VANDA PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
7 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PONVORY leads revenue
- • 5 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 11/25 completed
- • Speed: 13 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (5)
Discontinued (0)
Company Info
- First Approval
- 2009-05-06
- Latest
- 2026-02-20
- Applications
- 6
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges